Skip to main content
. 2021 Jul 2;2(1):zpab011. doi: 10.1093/sleepadvances/zpab011

Table 6.

Adverse event summary (safety analysis set)

Category, n (%) Placebo (n = 68) LEM5 (n = 69) LEM10 (n = 68) FLZ (n = 68)
Subjects with ≥1 TEAE 2 (2.9) 5 (7.2) 8 (11.8) 5 (7.4)
 Treatment-related TEAE 1 (1.5) 3 (4.3) 5 (7.4) 3 (4.4)
 Severe TEAE 0 0 0 0
 Serious TEAE 0 0 0 0
TEAEs in ≥2% of subjects in any active treatment group
 Somnolence 0 1 (1.4) 3 (4.4) 2 (2.9)

FLZ, flurazepam 30 mg; LEM5, lemborexant 5 mg; LEM10, lemborexant 10 mg; TEAE, treatment-emergent adverse event.